fig7

Figure 7. Effect of bosutinib in combination with paclitaxel, vinorelbine, or carboplatin on 3D spheroids from the MDR NSCLC NCI-H460/R cell line. (A) Spheroid viability after 72 and 96 h of drug treatment, assessed using the CellTiter-Glo® 3D Cell Viability Assay; (B) Representative spheroid morphology at the start of treatment (T0) and after 72 h (T72) and 96 h (T96) of drug treatment; (C) Quantification of spheroid area alterations after 72 and 96 h of drug treatment. Results are expressed as mean ± SEM of at least three independent experiments. Statistical significance was determined using an unpaired Student’s t-test. ^*P < 0.05; ^**P < 0.01; ^***P < 0.001; ^****P < 0.0001; ns: non-significant. MDR: Multidrug resistance; NSCLC: non-small cell lung cancer; SEM: standard error of the mean.